MGA Gene Biomedical Dossier
### **MGA Gene Dossier**

**Gene Identity & Clinical Context**
*   **HGNC ID:** 14010.
*   **OMIM Gene ID:** 616061.
*   **Primary Disease Associations:** MGA-related syndrome, a neurodevelopmental disorder with congenital anomalies. Other reported associations include premature ovarian failure 26 and spindle cell sarcoma.
*   **Clinical Significance Level:** The evidence for MGA's role in a novel neurodevelopmental syndrome is growing, but a larger cohort is needed to definitively establish its causative role in human disease.
*   **Inheritance Patterns Observed in Patients:** De novo heterozygous predicted loss-of-function variants have been observed in patients with MGA-related syndrome.

**Constraint & Variant Intolerance**
*   **pLI, LOEUF, pRec, pNull:** The gnomAD v2.1.1 constraint metrics for MGA are a pLI of 1.00, a LOEUF of 0.12 (with a 90% confidence interval of 0.08-0.21), pRec of 0.00, and pNull of 0.00.
*   **Clinical Interpretation of Constraint Scores:** A pLI score close to 1 (≥0.9 is the suggested cutoff) indicates that a gene is extremely intolerant to loss-of-function (LoF) variation. The low LOEUF score further supports that MGA is under strong selection against LoF variants. These scores suggest that MGA is likely a haploinsufficient gene.
*   **Variant Classes Most Likely to be Pathogenic:** Predicted loss-of-function variants, such as truncating variants (nonsense, frameshift), are most likely to be pathogenic.

**Phenotype Spectrum & HPO Terms**
*   **Primary HPO terms:**
    *   Global developmental delay (HP:0001263).
    *   Congenital heart defects (e.g., Atrial septal defect HP:0001631, Ventricular septal defect HP:0001629).
    *   Genitourinary anomalies (e.g., Cryptorchidism HP:0000028, Hypospadias HP:0000047).
    *   Craniofacial dysmorphism (e.g., High anterior hairline HP:0000290, Depressed nasal bridge HP:0005280).
    *   Hypotonia (HP:0001252).
    *   Hearing impairment (HP:0000365).
    *   Skeletal abnormalities (e.g., Pectus excavatum HP:0000767, Slender build HP:0001533).
    *   Feeding difficulties (HP:0011968).
    *   Intellectual disability.
    *   Epilepsy.
*   **Secondary HPO terms:**
    *   Abnormal brain imaging findings.
    *   Sleep dysfunction.
    *   Urinary issues.
    *   Autism.
*   **Age of Onset Patterns:** The observed phenotypes are typically congenital or manifest in early childhood.
*   **Phenotype Severity Spectrum:** The phenotypic spectrum is broad and can include developmental delays as well as multiple congenital anomalies.

**Genotype-Phenotype Correlations**
*   **Variant Classes and Their Typical Phenotypes:** Predicted loss-of-function variants in MGA are associated with a syndrome characterized by neurodevelopmental delays and a range of congenital anomalies, including cardiac, genitourinary, and craniofacial defects.
*   **Protein Domain-specific Phenotype Patterns:** The MGA protein has a T-box domain, which is predicted to interact with TBXT. Variants in TBXT have been linked to neural tube, genitourinary, and skeletal anomalies.
*   **Genotype-phenotype Correlation Strength:** There is emerging evidence for a correlation between de novo heterozygous loss-of-function MGA variants and a distinct neurodevelopmental and congenital anomaly syndrome. However, more extensive studies on larger patient cohorts are needed to solidify these correlations.
*   **Examples: specific variants → specific phenotypes:** De novo missense variants have been reported in individuals with early-onset Parkinson's disease, though detailed clinical information is limited.

**Clinical Variants & Phenotype Associations**
*   Due to the novelty of the MGA-related syndrome, a comprehensive list of well-characterized pathogenic variants with rsIDs and specific allele frequencies is not yet established in public databases like ClinVar. The primary evidence comes from case reports of de novo, heterozygous, predicted loss-of-function variants.

**Tissue Expression & Clinical Relevance**
*   **Highest Expressing Tissues (GTEx TPM):** According to the Human Protein Atlas, which incorporates GTEx data, MGA shows the highest expression in the testis, and also has notable expression in the cerebellum and other brain regions.
*   **Tissue-specific Phenotypes Expected:** The expression pattern in the brain aligns with the observed neurodevelopmental phenotypes such as developmental delay and intellectual disability. Expression in embryonic tissues is significant given the gene's role in embryogenesis and the presentation of congenital anomalies.
*   **Expression During Development and Age-Related Phenotypes:** MGA's role as a transcription factor is crucial during embryogenesis. The congenital nature of the associated phenotypes underscores its importance in early development.

**Molecular Mechanism & Phenotype Pathways**
*   **Normal Gene Function:** MGA functions as a dual-specificity transcription factor that regulates the expression of both MAX-network and T-box family target genes, which are important in embryogenesis.
*   **Disease Mechanism:** The proposed disease mechanism is haploinsufficiency resulting from heterozygous loss-of-function variants, suggesting that a reduced dosage of the MGA protein is sufficient to cause disease.
*   **Cellular/Molecular Pathways Disrupted → Phenotype Consequences:** MGA is part of the MYC/MAX/MGA pathway and typically acts as a repressor of MYC target genes, which are involved in cell proliferation. Loss of MGA function can lead to dysregulation of these target genes, potentially affecting cell cycle control and contributing to the observed developmental abnormalities.
*   **Protein-Protein Interactions Relevant to Phenotype:** MGA interacts with MAX, a key component of the MYC transcription factor network. It also interacts with a noncanonical PRC1 complex involved in gene repression.

**Diagnostic Yield & Clinical Utility**
*   **Diagnostic Yield in Clinical Cohorts:** The diagnostic yield of MGA variants in cohorts with neurodevelopmental disorders or congenital anomalies is still being determined as it is a relatively newly described disease gene.
*   **Most Common Reasons for Testing This Gene:** Testing for MGA variants would be considered in individuals presenting with a combination of global developmental delay, congenital heart defects, genitourinary anomalies in males, and craniofacial dysmorphisms.
*   **Clinical Actionability and Management Implications:** A genetic diagnosis can provide an explanation for the patient's phenotype, guide anticipatory care for associated features (e.g., cardiac and renal evaluations), and inform family planning.
*   **Genetic Counseling Considerations:** For de novo variants, the recurrence risk for future pregnancies of the parents is low, though germline mosaicism cannot be entirely excluded. A confirmed pathogenic variant allows for prenatal and preimplantation genetic testing options.

**Key Clinical Literature & Studies**
*   **PMID: 39600096, Year: 2025 (published online 2024), Key Phenotype Findings:** This study proposes MGA-related syndrome as a novel disorder based on individuals with de novo, heterozygous loss-of-function variants, characterized by developmental delays, cardiac anomalies, male genital malformations, craniofacial dysmorphisms, hypotonia, and hearing loss.
*   **PMID: 31862820, Year: 2019, Key Phenotype Findings:** This research identifies MGA as a negative regulator of the MYC pathway in lung adenocarcinoma, showing that MGA loss-of-function mutations are frequent in this cancer type. This establishes a key molecular function relevant to both cancer and development.

**HPO-Variant Matching Summary**
*   **High-confidence HPO-variant associations:** Heterozygous, predicted loss-of-function variants are strongly associated with a phenotype that includes Global developmental delay (HP:0001263), Congenital heart defects, and Genitourinary anomalies.
*   **Phenotype red flags:** The combination of significant developmental delay, a congenital heart defect, and genital malformations in a male patient should raise strong suspicion for an MGA-related disorder.
*   **Differential Diagnosis Considerations:** The phenotype of MGA-related syndrome can overlap with other neurodevelopmental syndromes. Therefore, a broad differential diagnosis should be considered, and diagnosis should be confirmed through genetic testing.

